Table 2.

Summary of clinical trials and the benefits of MHT regarding primary and secondary prevention of CVD

	Primary	Secondary	Time since menopause onset
	prevention	prevention	< 10 years	> 10 years
All-cause death	≈	≈	✓	≈
CV death	≈	≈	✓	≈
Stroke	✗	≈	≈	✗
Venous thromboembolism	✗	✗	✗	✗
Coronary heart disease	≈	≈	✓	≈

✓: beneficial effects

≈: neutral outcome

✗: detrimental effects